Journal of Chinese Pharmaceutical Sciences ›› 2020, Vol. 29 ›› Issue (10): 729-733.DOI: 10.5246/jcps.2020.10.068

• Original articles • Previous Articles     Next Articles

Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil

Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma*   

  1. Department of Pharmacy, Henan Provincial People’s Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou 450003, China
  • Received:2020-07-23 Revised:2020-09-10 Online:2020-10-31 Published:2020-09-15
  • Contact: Tel.: +86-371-65581026, E-mail:


Baloxavir marboxil is a polymerase acidic (PA) endonuclease inhibitor, which is approved by the U.S Food and Drug Administration (FDA) on October 25, 2018, for the treatment of uncomplicated influenza patients aged 12 years and older. In the present work, we reviewed the pharmacodynamics, pharmacokinetics, drug interactions, clinical trials and adverse reactions of baloxavir marboxil.

Key words: Baloxavir marboxil, Pharmacodynamics, Pharmacokinetics, Adverse reactions

CLC Number: